Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world
Anselm K. Gitt,
Dominik Lautsch,
Jean Ferrières,
Gaetano M. De Ferrari,
Ami Vyas,
Carl A. Baxter,
Lori D. Bash,
Veronica Ashton,
Martin Horack,
Wael Almahmeed,
Fu-Tien Chiang,
Kian Keong Poh,
Philippe Brudi,
Baishali Ambegaonkar
Affiliations
Anselm K. Gitt
Herzzentrum Ludwigshafen, Germany; Institut für Herzinfarktforschung, Ludwigshafen, Germany; Correspondence to: Herzzentrum Ludwigshafen, Med. Klinik B, Cardiology Department and Stiftung “Institut für Herzinfarktforschung”, Bremser Strasse 79, 67063 Ludwigshafen, Germany. Fax: +49 621 5034165.
Dominik Lautsch
Merck&Co, Inc., Kenilworth, NJ, USA
Jean Ferrières
Rangueil hospital, Toulouse university school of medicine, Toulouse, France
Gaetano M. De Ferrari
Department of Molecular Medicine University of Pavia, and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
Ami Vyas
Rutgers University, School of Public Health, Piscataway, NJ, USA
Carl A. Baxter
Merck Sharp & Dohme, Corp., Hertford Road, Hoddesdon, UK
Lori D. Bash
Merck&Co, Inc., Kenilworth, NJ, USA
Veronica Ashton
Agile-1 for Merck & Co., Inc., Kenilworth, NJ, USA
Martin Horack
Institut für Herzinfarktforschung, Ludwigshafen, Germany
Wael Almahmeed
Sheikh Khalifa Medical City, Abu Dhabi, UAE; Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, UAE
Fu-Tien Chiang
National Taiwan University Hospital, Taipei, Taiwan; Fu-Jen Catholic University Hospital, Taipei, Taiwan
Kian Keong Poh
Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Cardiology, National University Heart Center Singapore, National University Health System, Singapore
DYSIS II CHD was a longitudinal, observational study in 6794 patients from 18 countries. They were attending an outpatient physician appointment for coronary heart disease (CHD). 6370 patients (93.8%) were on active lipid lowering therapy (LLT). The mean atorvastatin dose equivalent was 25 mg per day and 10.5% received ezetimibe in combination with a statin. The mean low-density lipoprotein cholesterol (LDL-C) level was 88 mg/dL, with 29.4% of patients displaying a level below the 70 mg/dL target for very high-risk subjects. Conclusion: While more than 90% of patients with CHD were on lipid lowering drugs, only three out of ten patients achieved their LDL-C target value. Keywords: Low-density lipoprotein cholesterol, Treatment target, Global, Region, Statins
